Kornimate/medical-research-clean huggingface dataset:
prevention of narcotic-induced nausea

Conditions: Nausea

Summary: we are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). some doctors always give medicine to prevent the possible side effect of nausea, while others do not. we are looking to see if this extra medicine is helpful in preventing nausea. the goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants.

patients will be randomized to one of two study groups. they will then be asked to rate their pain and nausea on a line graph. if the patient is a female of child bearing age, a urine pregnancy test will be done per standard of care. after this, an iv catheter will be placed in a vein in the patients arm. pain medicine will be given through this iv per the doctor's order. with this medicine, patients will be given 10 milliliters (2 teaspoons) of either sodium chloride (salt water) or phenergan mixed with sodium chloride (salt water). phenergan is a medication typically used to help with nausea and is a common ingredient in prescription cough medicine. after this is finished, patients will be asked to rate their pain and nausea in 30 minutes, and again 1, 2, and 4 hours later. if the doctor decides the patient is able to be discharged from the emergency room before the 4 hours are up, they will be asked to rate your pain and nausea again before going home, and the study will be stopped at that time.

Eligibility criteria:
inclusion criteria: 1. patient in christian care emergency department 2. require intravenous narcotics for painful condition 3. ≥18 years of age 4. able to visually rate amount of pain and nausea exclusion criteria: 1. hypersensitivity to promethazine or opioids 2. patient requesting anti-emetic at enrollment 3. narcotic administration in last 6 hours 4. pregnancy or currently breast-feeding 5. known seizure disorder 6. medical instability

Keywords: narcotics nausea
loneliness and occurrence of suicide attempts and suicidal ideas

Conditions: Major Depressive Disorders

Summary: suicide is a major health problem that causes annually a million death worldwide. loneliness is known to be associated with suicidal ideation in minors and to be related with suicidal risk in elderly people. however little is known about this association in a middle-aged population. loneliness is a modifiable factor with suitable psychotherapeutic measures, it is essential to improve the scientific and medical knowledge about the link between this feeling and suicide risk in a population of depressed patients in middle age. the main objective is the study of the relationship between loneliness and the occurrence of suicidal behavior (sb) in major depressed adult population over 12 months. the secondary objectives are: * identification of risk factors (clinical, neuropsychological and biological) of the occurrence of sb within a clinical population and their interaction; * identification of predictive factors (clinical, neuropsychological, biological) therapeutic response to antidepressant in the context of depression.

this project is based on clinical, neuropsychological and biological data routinely collected in the department of emergency psychiatry and post acute care. this is a one year follow-up prospective study. over three years, 600 depressed patients will be recruited. * first visit (inclusion): clinical, biological and neuropsychological assessment * follow up visits (3, 6 and 12 months): clinical assessment only

Eligibility criteria:
inclusion criteria: main diagnosis of major depressive disorder according to diagnostic and statistical manual of mental disordersiv (dsm iv) having signed informed consent able to understand nature, aims, and methodology oh the study exclusion criteria: participation in another clinical trial patient on protective measures (guardianship or trusteeship)

Keywords: loneliness suicidal behavior depression
comparing diet and exercise approaches in women

Conditions: Diet Modification

Summary: the purpose of this study is to determine whether following a curves high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 30-days several times during 16 weeks of participating in the curves fitness program promotes stepwise reductions in body weight, improvements in body composition and/or improvements in markers of fitness and health better than following the weight watchers momentum program for the same time period.

the curves international fitness and weight loss program has become a very popular means of promoting health and fitness among women. the program involves a 30-minute circuit training program and a weight management program involving periods of moderate caloric restriction (1,200 to 1,600 calories per day) followed by short periods of higher caloric intake (2,600 calories per day). the program is designed to promote a gradual reduction in body fat while increasing strength and muscle mass/tone. researchers in the exercise and sport nutrition lab at texas a\&m university have conducted an extensive study on the effectiveness and safety of the curves fitness and diet program. results of this initial study have shown that the program promotes weight loss, improves markers of health, and improves fitness. the weight watchers program is another popular weight loss program. it provides a systematic approach to diet and exercise throughout the weight-loss process. consequently we are interested in comparing the efficacy of both programs to one another. the purpose of this study is to determine whether following a curves high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 30-days several times during 16 weeks of participating in the curves fitness program promotes stepwise reductions in body weight, improvements in body composition and/or improvements in markers of fitness and health better than following the weight watchers momentum program for the same time period.

Eligibility criteria:
inclusion criteria: * participant is female * participant is between the ages of 18 and 45 * participant is sedentary and overweight (bmi \> 27) exclusion criteria: * participant has any metabolic disorder including known electrolyte abnormalities, heart disease, arrhythmias, diabetes, thyroid disease, or hypogonadism; * participant has a history of hypertension, hepatorenal, musculoskeletal, autoimmune or neurological disease; * participant is taking thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive or androgenic medications; * participant has been pregnant or lactating within the past 12 months or are planning to become pregnant during the next 12 months; * participant is involved in a planned exercise program (\> 30 min./d. 3 d./wk.) within 3 - 6 months prior to the start of the study; * participant has taken any weight loss medications and/or dietary supplements that may affect muscle mass or body weight during the three month time period prior to beginning the study; * participant has a recent history of weight change (+/- 7 lbs. within the last 3 months).

Keywords: exercise intervention
parameters to assess response to intra-venous antibiotic treatment for pulmonary exacerbations in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: cystic fibrosis (cf) is a multisystem disease characterized by viscid secretions in multiple organ systems. lung infection and damage account for most of the disease burden. acute changes in respiratory signs and symptoms termed pulmonary exacerbations require treatment with intravenous antibiotics and hospital admission. these episodes cause substantial disruption to people's lives and impact on lung function, quality of life and lifespan. current treatment regimes require improvement but further study is needed to identify who might benefit from a different approach. this observational study aims to assess if multi-dimensional measurements taken during treatment correspond with later treatment response. this may allow us to personalise treatment more effectively in the future and to better understand how individuals respond to treatment.

pulmonary exacerbations in cf require treatment with intravenous (iv) antibiotics and hospital admission for between 10-21 days. these episodes cause substantial disruption to people's lives and impact on lung function, quality of life and lifespan.robust evidence to support current treatment approaches is lacking with awareness that current regimes could be optimised. as yet there is no model for predicting how patients with cf will respond to iv antibiotic treatment- other than clinical judgement and lung function response.this is due to lack of robust measures to identify clinical response at the time of treatment and safely predict later clinical outcomes. the heterogeneity of the 21st century cf population means a multi-dimensional composite measure is needed. this study has therefore been designed to provide an overall picture of people's response including clinical, biochemical and patient related outcome measures. using multi-dimensional assessment we hope the measures assessed in this study will give a better picture of how people feel and how they respond to treatment.

Eligibility criteria:
inclusion criteria: 1. patients attending the adult service with a confirmed diagnosis of cf by sweat test or genotype 2. able to provide written informed consent 3. able to understand and comply with protocol requirements and instructions 4. confirmed pulmonary exacerbation requiring treatment with intravenous antibiotics using defined criteria (physician and patient agreed need for admission for intravenous antibiotic treatment) exclusion criteria: 1. previous recipient of a lung or other solid organ transplant 2. inability to complete questionnaires 3. current enrolment in other investigational medicinal product randomised trial 4. admission for reasons other than pulmonary exacerbation of cf

Keywords: cystic fibrosis pulmonary exacerbation antibiotics outcome measures
the role of antibiotics after surgical treatment of simple hand infections: a prospective study

Conditions: Hand Infections

Summary: three patient groups with simple hand infections are tested regarding the necessity of antibiotics after surgical treatment.


Eligibility criteria:
inclusion criteria: * adult patients with simple hand infections exclusion criteria: * infection of the bone, tendon or joint * major diseases like diabetes or immunodeficiency * systemic manifestations like fever or lymphangitis * bite infections
prospective research in memory clinics (prime)

Conditions: Dementia; Mild Cognitive Impairment

Summary: the purpose of the prime study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia. approximately 4500 patients will be enrolled in this disease registry across 12 sites in australia. clinical, treatment, health status and economic data will be acquired over 3 years. the study will identify the relationships among demographic variables, prognostic features, geographic setting, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes.

a complete record of patient care will be collected to provide detailed information on the management and outcome of mild cognitive impairment and dementia and the profile of patients at participating sites. the data will be used to build models looking at the effect of management of these conditions on principal clinical events, health status and economic outcomes. this will provide the foundation for subsequent objective and prospective evaluation of evidence-based strategies for the optimal treatment of mild cognitive impairment and dementia in australia. this study is not prescriptive, but will instead examine the influence of a whole range of routinely used management strategies on clinical and economic outcomes among mild cognitive impaired and dementia patients in australia. this 'practice based' approach is increasingly widely used and is a useful tool for elucidating the relative effectiveness of different management strategies and for exploring relationships between patient characteristics, treatment and outcomes. observational study - no study drug administered.

Eligibility criteria:
inclusion criteria: * diagnosis of dementia under the dsm-iv criteria, or of mild cognitive impairment, using the peterson criteria * living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week) * patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy * availability of a caregiver willing to provide consent for required components of the study * fluent in english * may be participating in a phase iv or other post-marketing follow up study of an approved product for treatment of dementia exclusion criteria: * no concomitant life-threatening illness (a condition which is likely to interfere with the patient's ability to complete the study) * not unwilling or unable to complete the study * not concurrently participating in a clinical trial of an investigational drug (phase i, ii or iii) * unwillingness of patient or legal guardian / proxy to provide written informed consent * unwillingness of caregiver to provide written informed consent * for patients with diagnosis of mild cognitive impairment: current or previous treatment with any cholinesterase or memantine

Keywords: dementia mild cognitive impairment patient registries prospective studies longitudinal studies australia cholinesterase inhibitors observational non-randomized
a pre- and post- coronary artery bypass graft implantation disposed application of xenon

Conditions: Xenon; Sevoflurane; Anesthetics, Inhalation; Coronary Disease; Coronary Artery Bypass

Summary: the aim of this study is to determine whether xenon - as compared to sevoflurane - can be applied safely in patients for general anesthesia before and after cabg implantation.

the study will be conducted by two investigator types: the study enrollment and the post-anesthesia follow-up will be performed by investigator i who is blinded to the study treatment. investigator ii will only perform general anaesthesia for cabg surgery and will therefore necessarily be unblinded to the treatment conditions. patients will be randomly assigned to one of the following study groups. group 1 (xenon) will receive xenon for maintenance of balanced anesthesia for cabg surgery before and after extracorporal circulation. group 2 (sevoflurane) will receive sevoflurane for maintenance of balanced anesthesia for cabg surgery before and after extracorporal circulation. during extracorporal circulation, general anesthesia will be maintained intravenously in both groups.

Eligibility criteria:
inclusion criteria: * patients with coronary artery disease scheduled for elective cabg * patients willing and able to complete the requirements of this study * ejection fraction \> 50% * euroscore ≤ 8 * men and women \>= 50 yrs * women without childbearing potential * asa score ii-iv exclusion criteria: * lack of informed consent * euroscore \< 8 * mmse \< 24 * age \< 50 years * copd gold \> ii, increased need of oxygen * renal dysfunction * liver function disorders * acute coronary syndrome during the last 24 hours; hemodynamic instability * requirement of inotropic support * off-pump-surgery * disabling neuropsychiatric disorders * history of stroke with residuals * hypersensitivity to the study anaesthetics * increased intracranial pressure * pregnancy and lactation period * women of childbearing potential * presumed uncooperativeness or legal incapacity * participation in a concomitant trial

Keywords: xenon sevoflurane cardiac anesthesia cabg bypass surgery
reliability and validity of inline dynamometry study for measuring knee extensor torque

Conditions: Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Rupture; Anterior Cruciate Ligament Tear

Summary: this study will investigate the reliability and validity of an inline 'pull-type' dynamometer for measuring peak knee extensor torque. for the reliability study, healthy volunteers will be assessed by two assessors (inter-rater) at the index testing session, with testing repeated by one assessor one week later (test-retest). validity will be investigated against isometric electromechanical dynamometry (gold standard) in patients following anterior cruciate ligament (acl) reconstruction.

this is a prospective, cross sectional study using a within-participant, repeated measures design. the inter-rater and test-retest reliability of the kforce link (pull-type dynamometer) will be determine using 50 healthy subjects. the validity of the kforce link will be determined using 52 post-operative acl reconstruction patients against the gold standard of isometric electromechanical dynamometry (cybex). all testing will be performed isometrically with the knee positioned at 60 degrees knee flexion. assessors and participants will be blinded to the scores until testing is complete.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * no contraindications to maximal force testing (see exclusion criteria). * for the acl reconstruction participant cohort: diagnosed with acl injury that was managed with acl reconstruction surgery, with or without additional meniscal surgery. if medicated, stable dose of current regular medication for at least 4 weeks prior to study entry. * for the healthy control participant cohort: no current or previous history of significant lower limb injury, or a history of previous minor injury that is symptomatic at the time of recruitment. no previous lower limb surgery. no course of medication, whether prescribed or over the counter, other than vitamins and mineral supplements or, for females, oral contraceptives. exclusion criteria: * unable to provide written consent to study participation, or there are contraindications to maximal force testing, including the following: * history of chronic disease or disorder that may put the participants at risk because of participation in the study including non-united fractures, epilepsy, cardiac insufficiency, severe peripheral vascular disease, aneurysms, anticoagulant therapy, recent (\ 3 months), pregnancy, neurological disorders (e.g., parkinson's disease), skin conditions at point of force testing, severe osteoporosis, malignancy, rheumatoid arthritis. * conditions or symptoms that may influence the result of the study, or the participant's ability to participate in the study including pain, limited range of motion, knee effusion, or anaemia.

Keywords: dynamometer dynamometry hand held inline traction pull validity reliability
humoral immunity against sars-cov-2 in liver transplanted patients after covid-19 in comparison with immunocompetent patients

Conditions: Liver Transplant Infection; Covid19; Mortality; Immune Response

Summary: this is a prospective study analyzing the development of humoral immune response against sars-cov-2 in patients with previous covid19: the aim is to compare the incidence, titration and evolution of igg an igm in a prospective cohort of liver transplant patients surviving to the first wave of covid19, in comparison to not inmmunossupressed patients.

the liver transplant (ht) recipient population is more susceptible to infections than the general population. few data are available regarding the incidence and clinical course of sars-cov-2 infection in this population, initially considered to be "high risk" regarding a possible higher incidence and severity of infection in these patients. a prospective cohort of liver transplant recipient patients diagnosed with sars-cov-2 infection (clinical trials.gov protocol record hcb / 2020/0384) has been developed from seth (spanish society for liver transplantation). this study aims to analyze the incidence and establish the clinical evolution of the infection in these patients. initial data from the cohort, which includes 111 incidental cases diagnosed as of april 7, show a higher standardized incidence than the general population, but not higher mortality (data being published). the chronic immunosuppression in t solid organ transplant patients could play a double role with respect to sars-cov-2 infection: on the one hand, it may condition a greater susceptibility and initial aggressiveness, in relation to itself viral effect, and in the other hand, it could protect by reducing the immune response that triggers the pulmonary and systemic inflammatory process. after the initial covid-19 outbreak, both in the general population and in immunosuppressed patients, the rate of specific igm and igg seroconversion against this coronavirus, and its protective capacity against reactivations or reinfections, are unknown. therefore, it is a challenge for health organizations to identify the immune response in the population and to characterize its degree of protection, to adopt early measures to lessen the consequences of possible epidemic waves in the coming months. continuing with the prospective study of the cohort of liver transplant patients diagnosed with covid-19 (seth-covid-19), already defined and composed of 91 living patients, the humoral immune response and its evolution in the first 12 months after initial infection. the cohort will incorporate the new incidental cases; a comparative study will be carried out with a contemporary cohort of non-immunosuppressed patients, controlled for age, gender and severity of the initial disease.

Eligibility criteria:
inclusion criteria: patients recovered of covid 19 informed consent exclusion criteria: chemotherapy on going concomitant autoimmune diseases

Keywords: humoral immunity reinfection igg and igm against sars-cov-2 immunosuppression
impact of direct outreach to expand access to naloxone in the context of standing orders

Conditions: Opioid Abuse; Overdose; Risk Behavior

Summary: in the setting of naloxone standing orders, this study will assess if direct outreach with a web-based "naloxone navigator 1.0" to patients prescribed chronic opioid therapy (cot) changes opioid risk behaviors, increases naloxone uptake, and increases knowledge about overdose and naloxone

this is a randomized study of a web-based naloxone educational resource (naloxone navigator 1.0) for adults prescribed chronic opioid therapy. this study will be conducted under new naloxone standing order legislation passed in colorado. the naloxone navigator 1.0 will provide online training on how to recognize an opioid overdose and respond using naloxone. there will be two arms: one will receive a link to the naloxone navigator 1.0 and the other will receive usual care (no link). outcomes will include opioid risk behavior, overdose and naloxone knowledge, naloxone dispensings, and overdose rates.

Eligibility criteria:
inclusion criteria: * 18 years of age or greater prescribed chronic opioid therapy exclusion criteria: * non-english speaking, hospice enrollment, do-not-resuscitate order, receipt of naloxone in the last 12 months, no internet access, not planning to continue to receive care in the same setting for the next 4 months.